Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

2011, Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials, Lancet, 378, 771, 10.1016/S0140-6736(11)60993-8 2005, Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials, Lancet, 365, 1687, 10.1016/S0140-6736(05)66544-0 Swain, 1996, Tamoxifen: the long and short of it, J Natl Cancer Inst, 88, 1510, 10.1093/jnci/88.21.1516 Peto, 1996, Five years of tamoxifen—or more?, J Natl Cancer Inst, 88, 1791, 10.1093/jnci/88.24.1791 Fisher, 2005, Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study, J Natl Cancer Inst, 97, 1652, 10.1093/jnci/dji372 Fisher, 1996, The worth of 5 versus more than 5 years of tamoxifen therapy for breast cancer patients with negative nodes and estrogen-receptor positive tumors: an update of NSABP B-14, J Natl Cancer Inst, 88, 1529, 10.1093/jnci/88.21.1529 Tormey, 1996, Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer, J Natl Cancer Inst, 88, 1828, 10.1093/jnci/88.24.1828 Stewart, 1996, Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer, Br J Cancer, 74, 297, 10.1038/bjc.1996.356 1995 Gray, 2000, Tamoxifen for early breast cancer: better late than never, Ann Oncol, 11, 505, 10.1023/A:1008323116265 Earl, 1997, The optimal duration of tamoxifen treatment for breast cancer remains uncertain: randomize into aTTom, Clin Oncol (R Coll Radiol), 9, 141, 10.1016/S0936-6555(97)80067-2 Gray, 2008, ATTom: randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor-positive (ER+) or ER untested breast cancer—preliminary results, Proc Am J Clin Oncol, 26 Davies, 1998, Variation in use of adjuvant tamoxifen, Lancet, 351, 1487, 10.1016/S0140-6736(05)78869-3 1992 Li, 2002, Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older, Cancer Epidemiol Biomarkers Prev, 11, 601 Goss, 2006, Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial, Semin Oncol, 33, S8, 10.1053/j.seminoncol.2006.03.025 1990, Introduction and methods Love, 1991, Effects of tamoxifen on cardiovascular risk factors in post-menopausal women, Ann Intern Med, 115, 860, 10.7326/0003-4819-115-11-860 McDonald, 1991, Fatal myocardial infarction in the Scottish Adjuvant Tamoxifen Trial, BMJ, 303, 435, 10.1136/bmj.303.6800.435 Guetta, 1995, Effects of the antioestrogen tamoxifen on low density lipoprotein concentrations and oxidation in post-menopausal women, Am J Cardiol, 76, 1072, 10.1016/S0002-9149(99)80302-6 2011, Effects on 11 year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals, Lancet, 378, 2013, 10.1016/S0140-6736(11)61125-2 Dowsett, 2010, Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen, J Clin Oncol, 28, 509, 10.1200/JCO.2009.23.1274